Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for ...

Completed the first Good Manufacturing Practice (GMP) batch of drug substance PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in ...

Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory ... qualify manufacturers to provide API and manufacture drug product; our ability to enter into commercial ...

Thomas Bieber, University of Bonn, Germany, wasted no time in welcoming his colleagues from around the world to the ...

The microbiome study revealed consistent levels of ß-glucuronidase across different species and conditions, supporting the activation mechanism of PALI-2108. The consistent abundance of this enzyme ...

Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects, potential ...

This orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development ... to provide API and manufacture drug product; our ability to enter into commercial ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

The introduction of PDE5 inhibitors as safe and well-tolerated orally active drugs for the treatment of ... The application of PDE4 inhibitors appears to be a promising option to facilitate ...